#USA #New York #Clinical Trial #Longevity #NOVOS

NOVOS Core Clinical Trial Affirms Cardiovascular Health Benefits for Individuals Over 40

In a groundbreaking study, NOVOS, a biotechnology company dedicated to promoting longevity, has released findings from a recent clinical trial highlighting significant cardiovascular benefits in aging adults. This randomized and double-blind trial tested the NOVOS Core nutritional intervention on participants aged 40 and above, ultimately unveiling compelling data on its positive effects on vascular health.

Trial Overview and Methodology

Conducted by researchers at the University of Surrey, UK, the trial enrolled participants without pre-existing cardiovascular diseases. The research team aimed to assess how the multi-component NOVOS Core supplement could impact various cardiovascular health markers over the course of six months. Notably, the trial is registered under ClinicalTrials.gov (NCT06145087) and has garnered considerable attention in the scientific community with its manuscript currently under peer review.

The outcome of the study has shown that participants who took the NOVOS Core supplements exhibited remarkable enhancements in endothelial function — a crucial indicator of vascular health — with sustained improvements observed even six months after the intervention period. In contrast, the placebo group exhibited no significant changes in the same metrics.

Key Findings from the Study

The results from the trial underscore three primary areas of improvement among participants receiving the NOVOS Core intervention:

1. Improved Endothelial Function: An initial enhancement of +2.9% in flow-mediated dilation (FMD) was observed shortly after the first dosage. The results remain significant over the entire trial duration, showcasing that using this nutritional supplement could yield an improvement comparable to that seen in rigorous aerobic exercise regimens.

2. Enhanced Arterial Flexibility: At the six-month mark, there was a notable reduction in pulse wave velocity — a key measure of arterial stiffness — by -1.18 m/s compared to the placebo. This improvement suggests a slower rate of age-related vascular decline, marking a substantial departure from the expected trajectories generally seen as adults age.

3. Support for Healthy Blood Pressure Levels: Participants using the NOVOS Core supplement experienced a reduction in systolic blood pressure of -6.1 mmHg when contrasted with the placebo group. Maintaining blood pressure within healthy parameters is vital for long-term cardiovascular function.

The significance of these findings cannot be overstated, especially considering that the changes were observed independently of any notable shifts in lipid levels, indicating a direct and beneficial influence of the NOVOS Core on vascular biology.

Implications for Aging and Longevity

Academic leaders in the study including Professor Christian Heiss, MD, from the University of Surrey, stated that the results provide preliminary evidence that targeting various biological mechanisms governing vascular aging could be beneficial for heart health, especially before the onset of any cardiovascular diseases. The multi-compound strategy employed in NOVOS Core could revolutionize how the industry approaches nutritional interventions aimed at promoting longevity.

Moreover, these findings bear substantial implications for preventive health measures. The risks traditionally associated with aging in vascular health may not be as irreversible as once perceived. The study presents an argument for a proactive approach toward nutritional strategies that support vascular health, which can lead to enhanced quality of life as people age.

About NOVOS

Founded in 2019, NOVOS is positioned at the forefront of biotechnology and longevity. Committed to developing science-backed solutions to promote healthy aging, NOVOS products are grounded in the twelve biological hallmarks of aging and supported by comprehensive research, from preclinical trials to current human studies. As a Public Benefit Corporation, NOVOS is also dedicated to fostering advancements in aging science through collaborations with academic institutions and nonprofit organizations.

In summary, the NOVOS Core clinical trial not only affirms the potential cardiovascular benefits for aging adults but also serves to inspire future research and developments in the field of longevity. With such promising results, the quest for effective aging interventions continues to gain momentum.